BioMed X, the Heidelberg-based research institute, has announced a new collaboration with Novo Nordisk. The mission? Crack one of pharma’s toughest challenges: making peptide drugs work better when taken orally.
Right now, most peptide-based therapies struggle with:
- Low absorption in the gut.
- Rapid digestion and clearance.
- Poor patient convenience compared to injectables.
This project aims to change all that.
The New Project: Prolonged Retention in the Gut
The initiative is called: “Prolonged Retention of Oral Peptide Formulations in the Gut.”
Here’s the goal in plain English:
- Develop tablets or capsules that stick around longer in the small intestine.
- Release the drug gradually for better absorption.
- Improve bioavailability without compromising gut safety.
If successful, this could make peptide drugs like GLP-1 agonists—currently reshaping diabetes and obesity treatment—more effective and easier to take.
Why Oral Peptides Are So Hard
Despite decades of research, oral peptides face huge barriers:
- The intestine clears drugs too fast.
- Peptides don’t easily cross intestinal walls.
- Formulations often fail before absorption can happen.
This new project tackles these problems head-on with novel retention technologies.
Voices from the Leaders
Dr. Christian Tidona, CEO of BioMed X, said it best:
“Making peptide drugs orally available via new technologies will have a major impact on patients’ lives.”
From Novo Nordisk, Stephen Buckley added:
“We launched the first oral biologic on the market. Now, we want to push the boundaries even further.”
The Opportunity for Researchers
BioMed X is calling for global talent. Scientists interested in joining this initiative can submit proposals by October 12, 2025 through the BioMed X Career Space.
This is a rare chance to work at the intersection of:
- Industry and academia.
- Basic science and drug development.
- Cutting-edge formulation and real-world impact.
The Bigger Picture
Why does this matter? Because oral delivery could:
- Increase patient compliance (no injections).
- Expand access to life-changing therapies.
- Redefine how chronic conditions like diabetes and obesity are treated.
With BioMed X’s crowdsourcing model and Novo Nordisk’s track record in diabetes innovation, this partnership has the potential to accelerate breakthroughs.
Final Takeaway
If they succeed, peptide therapies may finally move from syringes to simple pills. For patients, that’s not just convenience—it’s freedom.
